



FOR IMMEDIATE RELEASE

SPARC enters into an exclusive worldwide license agreement for SCD-153 with JHU and IOCB

- *First-in-class topical formulation for the treatment of Alopecia Areata*
- *IND approved by DCGI*

Mumbai, India, November 2, 2023 – Sun Pharma Advanced Research Company Ltd. (Reuters: SPRC.BO, Bloomberg: SPADV IN, NSE: SPARC, BSE: 532872, "SPARC") today announced that it has entered into an agreement with Johns Hopkins University (JHU) and The Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences (IOCB) (Licensors) to exclusively license SCD-153 including all patents and patent applications owned or controlled by licensors.

SPARC had evaluated SCD-153 under a Material Transfer Agreement (MTA) after which it entered into an Option to License Agreement with the licensors. SPARC's IND was approved by Drug Controller General of India (DCGI).

Under the terms of the agreement, the licensors are eligible for upfront payment, milestone payments contingent upon the achievement of regulatory and sales milestones, as well as tiered royalties on sales.

"The licensing of SCD-153 marks another successful collaboration between SPARC and an academic institute under our outreach program with academia. Topical SCD-153, upon successful development, can provide an important option to clinicians and patients for the treatment of Alopecia Areata " said Anil Raghavan, CEO of SPARC.

About SCD-153:

SCD-153 is a first-in-class topical drug for the treatment of alopecia areata developed jointly by SPARC, JHU and IOCB. SCD-153 inhibits pro-inflammatory pathways such as TET2, IFN- β , I κ Bz mediated IL-6 and inflammasome pathways. It also stimulates the antioxidant KEAP1/Nrf2 pathway. In-vivo experiments have established that SCD-153 hastens the transition of hair follicles from the telogen to anagen phase leading to hair growth.



About Sun Pharma Advanced Research Company Ltd. (CIN - L73100GJ2006PLC047837):

Sun Pharma Advanced Research Company Ltd. (SPARC) is a clinical stage bio-pharmaceutical company focused on continuously improving standards of care for patients globally, through innovation in therapeutics and delivery. SPARC aims to advance availability of treatment options for patients across the world. More information about the company can be found at www.sparc.life

Contact

Jaydeep Issrani

Tel +91 22 66455645, Ext: 5787

Tel Direct +91 22 6645 5787

Mobile +91-9820216916

E-mail jaydeep.issrani@sparcmail.com

Disclaimer:

Statements in this "Document" describing the Company's objectives, projections, estimates, expectations, plans or predictions or industry conditions or events may be "forward looking statements" within the meaning of applicable securities laws and regulations. Actual results, performance or achievements could differ materially from those expressed or implied. The Company undertakes no obligation to update or revise forward looking statements to reflect developments or circumstances that arise or to reflect the occurrence of unanticipated developments/circumstances after the date hereof.